LLY Logo

Eli Lilly and Company (LLY) 

NYSE
Market Cap
$732.88B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
370 of 776
Rank in Industry
6 of 10

Largest Insider Buys in Sector

LLY Stock Price History Chart

LLY Stock Performance

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal …

Insider Activity of Eli Lilly and Company

Over the last 12 months, insiders at Eli Lilly and Company have bought $0 and sold $2.35B worth of Eli Lilly and Company stock.

On average, over the past 5 years, insiders at Eli Lilly and Company have bought $478.61M and sold $5.56B worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 29,992,668 shares for transaction amount of $374.91M was made by Kearny Acquisition Corp (director) on 2022‑11‑30.

List of Insider Buy and Sell Transactions, Eli Lilly and Company

2024-09-03Sale10 percent owner
24,084
0.0026%
$966.69$23.28M-5.05%
2024-08-27Sale10 percent owner
24,552
0.0026%
$968.46$23.78M-4.37%
2024-08-26SaleSVP, Finance, & CAO
750
<0.0001%
$950.00$712,500-3.94%
2024-08-22Sale10 percent owner
3,196
0.0003%
$966.33$3.09M-4.26%
2024-07-10Sale10 percent owner
210,000
0.023%
$939.82$197.36M0.00%
2024-07-08Sale10 percent owner
93,593
0.01%
$918.64$85.98M0.00%
2024-07-05Sale10 percent owner
52,369
0.0056%
$915.18$47.93M0.00%
2024-07-03Sale10 percent owner
8,848
0.0009%
$915.31$8.1M0.00%
2024-07-01Sale10 percent owner
58,749
0.0063%
$915.26$53.77M0.00%
2024-06-28Sale10 percent owner
1,441
0.0002%
$915.02$1.32M0.00%
2024-06-25Sale10 percent owner
188,100
0.0198%
$903.82$170.01M+0.17%
2024-06-24Sale10 percent owner
17,229
0.0018%
$902.38$15.55M+1.77%
2024-06-20Sale10 percent owner
9,671
0.0011%
$902.67$8.73M+2.18%
2024-06-17Sale10 percent owner
194,978
0.021%
$885.91$172.73M+2.23%
2024-06-14Sale10 percent owner
15,022
0.0016%
$882.47$13.26M+2.98%
2024-06-10Sale10 percent owner
75,510
0.0079%
$860.78$65M+4.36%
2024-06-07Sale10 percent owner
139,490
0.0147%
$852.29$118.89M+6.12%
2024-06-06Sale10 percent owner
179,617
0.0189%
$837.82$150.49M+7.64%
2024-06-05Sale10 percent owner
20,383
0.0022%
$836.32$17.05M+8.36%
2024-06-03Sale10 percent owner
192,794
0.0202%
$829.77$159.97M+8.25%

Insider Historical Profitability

18.03%
LECHLEITER JOHN Cformer director
160068
0.0169%
$772.0112<0.0001%
Ricks David APresident & CEO
157405
0.0166%
$772.0116+34.48%
Skovronsky DanielSVP, CSO, and Pres. LRL
75818
0.008%
$772.0120+34.08%
TAI JACKSON P
62857
0.0066%
$772.01120+14.08%
White Anne E.EVP & Pres, Lilly Neuroscience
57926
0.0061%
$772.0112+34.48%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Lilly Endowment$76.94B10.4198.9M-0.87%-$676.83M100
The Vanguard Group$56.59B7.6572.75M+1.58%+$882.06M1.04
BlackRock$50.78B6.8765.27M+1.41%+$706.35M1.11
PNC Financial Services$40.02B5.4151.44M-0.53%-$211.04M27.99
State Street$26.65B3.6134.26M+1.4%+$366.61M1.09
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.